ABIONYX Pharma SA (0RAG) Income Statement
ABIONYX Pharma SA Income Statement
Last quarter (Q2 2026), ABIONYX Pharma SA's total revenue was $1.93M, a decrease of 17.53% from the same quarter last year. In Q2, ABIONYX Pharma SA's net income was $-4.81M. See ABIONYX Pharma SA’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 4.06M | $ 4.60M | $ 4.64M | $ 5.25M | $ 675.00K | |
| $ 376.00K | $ 844.00K | $ 618.00K | $ 636.00K | $ 259.00K | |
| $ 6.63M | $ 5.31M | $ 4.03M | $ 4.75M | $ 6.21M | |
| Depreciation and Amortization | $ 551.00K | $ 135.00K | $ 153.00K | $ 135.00K | $ 119.00K |
| $ -5.70M | $ -5.27M | $ -4.53M | $ -4.01M | $ -7.42M | |
| $ -6.25M | $ -5.57M | $ -3.41M | $ -4.11M | $ -5.95M | |
| $ 17.00K | $ 84.00K | $ -106.00K | $ -97.00K | $ 130.00K | |
| $ -6.24M | $ -5.47M | $ -3.52M | $ -4.21M | $ -5.82M | |
| $ -5.55M | $ -4.40M | $ -3.52M | $ -4.21M | $ -5.82M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.16 | $ -0.13 | $ -0.12 | $ -0.15 | $ -0.23 |
| Diluted EPS | $ -0.16 | $ -0.13 | $ -0.12 | $ -0.15 | $ -0.23 |
| Weighted Average Shares Outstanding | 35.51M | 33.70M | 29.35M | 27.97M | 24.88M |
| Weighted Average Shares Outstanding (Diluted) | 35.51M | 33.70M | 29.35M | 27.97M | 24.88M |
Currency in EUR
